TY -的T1 - MS治疗依从性和复发的风险(P01.193) JF -神经学乔-神经病学SP - P01.193 LP - P01.首页193六世- 80 - 7补充AU -布鲁斯·科恩AU -托马斯Leist盟Patricia Coyle AU -霍华德Zwibel盟-克莱德马科维茨AU -马克Tullman Y1 - 2013/02/12 UR - //www.ez-admanager.com/content/80/7_Supplement/P01.193.abstract N2 -目的:调查之间的关系,坚持疾病修饰治疗(DMT)和多发性硬化症(MS)复发的治疗优化女士(MS)研究。背景:药物治疗依从性的程度,患者符合建议治疗剂量和频率。证据表明,对患者治疗依从性是至关重要的减少复发女士缺乏。设计/方法:学者女士在前,一个准,开放研究,被诊断出患有MS和对待glatiramer醋酸或β干扰素由专业药房分发。签署知情同意被返回到药店。研究研究网站登记注销生产指令。在基线反应进入开始,定期。依从性,药物持有率(MPR)来衡量,也来源于药房发货记录。Logistic regression examined the association between physician confirmed relapses and DMT, therapy MPR (< 0.5; >0.5 to <0.9; > 0.9), number of prior MS therapies, and time since first symptoms.RESULTS: Across all therapies, the mean MPR for the interim completer cohort of 1,309 was 0.9 (range: 0.1 to 1.0), with 63.8% reaching a two-year MPR >=0.9. Evaluated by categories of MPR, the proportion of participants remaining relapse-free for 24 months increased with increasing MPR, and the proportion with one or more relapses declined with increasing levels of MPR (p < 0.003). Regression analysis revealed the odds of relapse for a patient in the MPR >=0.9 MPR group was 0.5058, 50% of that of a patient in the MPR <=0.5 category (p = 0.02). Being treated with one or more DMT prior to the current one increased the likelihood of relapse 1.7 times (odds ratio = 1.6933) compared to no prior treatments (p < 0.001).CONCLUSIONS: Better DMT adherence is associated with fewer MS relapses. Independent of adherence, one or more DMT changes increase the likelihood of relapses.Supported by: Teva Pharmaceuticals.Disclosure: Dr. Cohen has received personal compensation for activities with Astellis, Biogen Idec, EMD Serono, Genzyme Corporation, Sanofi-Aventis Pharmaceuticals, Inc., and Teva Neurscience. Dr. Cohen has received research support from Teva Neuroscience, the National Institutes of Health, Biogen Idec, EMD Serono, Novartis, and Roche. Dr. Leist has received personal compensation for activities with EMD Serono, Teva Neuroscience, Biogen, Bayer, and Pfizer as a consultant. Dr. Leist has received research support from EMD Serono, Teva Neuroscience, Bayer, ONO, Novartis Daishi, Acorda. Dr. Coyle has received personal compensation for activities with Acorda Therapeutics, Bayer, Biogen Idec, Genentech, Inc., Novartis, Pfizer Inc, Questcor, Roche Diagnostics Corporation, Sanofi-Aventis Pharmaceuticals Corporation, and Teva Neuroscience. Dr. Coyle has received personal compensation in an editorial capacity for NEURA. Dr. Coyle has received research support fromActelion, EMD Serono, and Novartis. Dr. Zwibel has received personal compensation for activities with Acorda Therapeutics, Bayer Pharmaceuticals Corporation, Biogen Idec, Serono, Inc., Genentech, Inc., and Teva Neuroscience as a consultant and/or member of speaker bureau. Dr. Markowitz has received personal compensation for activities with Bayer, Biogen-Idec, Eli Lilly, EMD-Serono, and Teva Neuroscience as a consultant. Dr. Tullman has received personal compensation for activities with Allergan, Inc., Acorda Therapeutics, Biogen Idec, EMD Serono, Novartis, Pfizer Inc, Questcor, Teva Neuroscience, and Sanofi-Aventis Pharmaceuticals, Inc.Monday, March 18 2013, 2:00 pm-6:30 pm ER -